DONS_HUMAN
ID DONS_HUMAN Reviewed; 566 AA.
AC Q9NYP3; Q8NC53; Q9NSR9; Q9NVZ5; Q9NYP1; Q9NYP2;
DT 11-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT 11-JAN-2001, sequence version 2.
DT 03-AUG-2022, entry version 151.
DE RecName: Full=Protein downstream neighbor of Son;
DE AltName: Full=B17;
GN Name=DONSON; Synonyms=C21orf60;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC TISSUE=Teratocarcinoma;
RX PubMed=14702039; DOI=10.1038/ng1285;
RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA Isogai T., Sugano S.;
RT "Complete sequencing and characterization of 21,243 full-length human
RT cDNAs.";
RL Nat. Genet. 36:40-45(2004).
RN [2]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC TISSUE=Testis;
RX PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA Wiemann S., Schupp I.;
RT "The full-ORF clone resource of the German cDNA consortium.";
RL BMC Genomics 8:399-399(2007).
RN [3]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC TISSUE=Mammary gland;
RX PubMed=15489334; DOI=10.1101/gr.2596504;
RG The MGC Project Team;
RT "The status, quality, and expansion of the NIH full-length cDNA project:
RT the Mammalian Gene Collection (MGC).";
RL Genome Res. 14:2121-2127(2004).
RN [4]
RP NUCLEOTIDE SEQUENCE [MRNA] OF 108-566 (ISOFORMS 1; 2 AND 3).
RX PubMed=10773462; DOI=10.1016/s0378-1119(00)00089-5;
RA Slavov D., Hattori M., Sakaki Y., Rosenthal A., Shimizu N., Minoshima S.,
RA Kudoh J., Yaspo M.-L., Ramser J., Reinhardt R., Reimer C., Clancy K.,
RA Rynditch A., Gardiner K.;
RT "Criteria for gene identification and features of genome organization:
RT analysis of 6.5 Mb of DNA sequence from human chromosome 21.";
RL Gene 247:215-232(2000).
RN [5]
RP SPLICE ISOFORM(S) THAT ARE POTENTIAL NMD TARGET(S).
RX PubMed=14759258; DOI=10.1186/gb-2004-5-2-r8;
RA Hillman R.T., Green R.E., Brenner S.E.;
RT "An unappreciated role for RNA surveillance.";
RL Genome Biol. 5:R8.1-R8.16(2004).
RN [6]
RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC TISSUE=Cervix carcinoma;
RX PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA Elledge S.J., Gygi S.P.;
RT "A quantitative atlas of mitotic phosphorylation.";
RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN [7]
RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-28 AND SER-34, AND
RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC TISSUE=Cervix carcinoma, and Erythroleukemia;
RX PubMed=23186163; DOI=10.1021/pr300630k;
RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA Mohammed S.;
RT "Toward a comprehensive characterization of a human cancer cell
RT phosphoproteome.";
RL J. Proteome Res. 12:260-271(2013).
RN [8]
RP INVOLVEMENT IN MIMIS, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RX PubMed=28630177; DOI=10.1101/gr.219899.116;
RA Evrony G.D., Cordero D.R., Shen J., Partlow J.N., Yu T.W., Rodin R.E.,
RA Hill R.S., Coulter M.E., Lam A.N., Jayaraman D., Gerrelli D., Diaz D.G.,
RA Santos C., Morrison V., Galli A., Tschulena U., Wiemann S., Martel M.J.,
RA Spooner B., Ryu S.C., Elhosary P.C., Richardson J.M., Tierney D.,
RA Robinson C.A., Chibbar R., Diudea D., Folkerth R., Wiebe S.,
RA Barkovich A.J., Mochida G.H., Irvine J., Lemire E.G., Blakley P.,
RA Walsh C.A.;
RT "Integrated genome and transcriptome sequencing identifies a noncoding
RT mutation in the genome replication factor DONSON as the cause of
RT microcephaly-micromelia syndrome.";
RL Genome Res. 27:1323-1335(2017).
RN [9]
RP INVOLVEMENT IN MISSLA, VARIANTS MISSLA ARG-278; CYS-282; LEU-292;
RP 293-ARG--SER-566 DEL; 417-ASN-SER-418 DEL; 419-LYS--SER-566 DEL;
RP 428-GLN--SER-566 DEL; SER-433; THR-446; THR-489; LYS-504; LYS-543 INS AND
RP 563-ASN--SER-566 DEL, CHARACTERIZATION OF VARIANTS MISSLA CYS-282; LEU-292;
RP 417-ASN-SER-418 DEL; THR-446; THR-489 AND LYS-543, VARIANT ARG-28,
RP CHARACTERIZATION OF VARIANT ARG-28, FUNCTION, SUBCELLULAR LOCATION,
RP INDUCTION, IDENTIFICATION IN THE REPLISOME COMPLEX, AND INTERACTION WITH
RP MCM2; MCM7; PCNA AND TICRR.
RX PubMed=28191891; DOI=10.1038/ng.3790;
RA Reynolds J.J., Bicknell L.S., Carroll P., Higgs M.R., Shaheen R.,
RA Murray J.E., Papadopoulos D.K., Leitch A., Murina O., Tarnauskaite Z.,
RA Wessel S.R., Zlatanou A., Vernet A., von Kriegsheim A., Mottram R.M.,
RA Logan C.V., Bye H., Li Y., Brean A., Maddirevula S., Challis R.C.,
RA Skouloudaki K., Almoisheer A., Alsaif H.S., Amar A., Prescott N.J.,
RA Bober M.B., Duker A., Faqeih E., Seidahmed M.Z., Al Tala S., Alswaid A.,
RA Ahmed S., Al-Aama J.Y., Altmueller J., Al Balwi M., Brady A.F., Chessa L.,
RA Cox H., Fischetto R., Heller R., Henderson B.D., Hobson E., Nuernberg P.,
RA Percin E.F., Peron A., Spaccini L., Quigley A.J., Thakur S., Wise C.A.,
RA Yoon G., Alnemer M., Tomancak P., Yigit G., Taylor A.M., Reijns M.A.,
RA Simpson M.A., Cortez D., Alkuraya F.S., Mathew C.G., Jackson A.P.,
RA Stewart G.S.;
RT "Mutations in DONSON disrupt replication fork stability and cause
RT microcephalic dwarfism.";
RL Nat. Genet. 49:537-549(2017).
CC -!- FUNCTION: Replisome component that maintains genome stability by
CC protecting stalled or damaged replication forks. After the induction of
CC replication stress, required for the stabilization of stalled
CC replication forks, the efficient activation of the intra-S-phase and
CC G/2M cell-cycle checkpoints and the maintenance of genome stability.
CC {ECO:0000269|PubMed:28191891}.
CC -!- SUBUNIT: Component of the replisome complex composed of at least
CC DONSON, MCM2, MCM7, PCNA and TICRR; interaction at least with PCNA
CC occurs during DNA replication. {ECO:0000269|PubMed:28191891}.
CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:28191891}.
CC Note=Localizes at DNA replication sites. {ECO:0000269|PubMed:28191891}.
CC -!- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=3;
CC Comment=Experimental confirmation may be lacking for some isoforms.;
CC Name=1;
CC IsoId=Q9NYP3-1; Sequence=Displayed;
CC Name=2;
CC IsoId=Q9NYP3-2; Sequence=VSP_004192, VSP_004193;
CC Name=3;
CC IsoId=Q9NYP3-3; Sequence=VSP_004194, VSP_004195;
CC -!- TISSUE SPECIFICITY: Expressed in the brain, with higher levels in
CC prenatal compared to adult brain. {ECO:0000269|PubMed:28630177}.
CC -!- DEVELOPMENTAL STAGE: Expressed during embryonic development. At
CC Carnegie stage 22 (about 7.5 weeks gestation), expressed in numerous
CC tissues, including brain, heart, lung, gastrointestinal tract, kidney,
CC hind limb and forelimb digits. Similar expression is observed at 9
CC weeks of gestation. In the brain of a 9-week old fetus, prominently
CC expressed in the neocortex subventricular zone and in the cortical
CC plate and also detected in the ganglionic eminences. At 12 weeks of
CC gestation, expression in the fetal brain is prominent in the basal
CC ganglia and the ventricular and subventricular zones and cortical plate
CC of the neocortex, mesencephalon, and rhombencephalon. At 15 and 16
CC weeks, highly expressed in the ventricular and subventricular zones,
CC respectively. Highly expressed in the ganglionic eminence of 15 week-
CC old brain and subplate of 16 week-old brain. At 20 weeks of gestation,
CC expressed in the ventricular and subventricular zones, intermediate
CC zone, and cortical plate of the neocortex. At 21 weeks of gestation,
CC expressed in the neocortex with highest levels in the cortical plate.
CC {ECO:0000269|PubMed:28630177}.
CC -!- INDUCTION: Expression is cell-cycle dependent with highest levels
CC during S phase. {ECO:0000269|PubMed:28191891}.
CC -!- DISEASE: Microcephaly-micromelia syndrome (MIMIS) [MIM:251230]: A
CC severe autosomal recessive disorder characterized by intrauterine
CC growth restriction, marked microcephaly, craniofacial anomalies,
CC skeletal dysplasia, and variable malformations of the limbs,
CC particularly the upper limbs. It usually results in death in utero or
CC in the perinatal period. {ECO:0000269|PubMed:28630177}. Note=The
CC disease is caused by variants affecting the gene represented in this
CC entry. This extremely rare syndrome is caused by an intronic mutation
CC that leads to the retention of intron 6, probably resulting in non-
CC sense mediated mRNA decay. This isoform has also been detected in
CC healthy tissues, but at much lower levels than in MIMIS samples.
CC {ECO:0000269|PubMed:28630177}.
CC -!- DISEASE: Microcephaly, short stature, and limb abnormalities (MISSLA)
CC [MIM:617604]: An autosomal recessive disorder characterized by
CC intrauterine growth retardation, microcephaly, variable short stature,
CC and limb abnormalities mainly affecting the upper limb and radial ray.
CC Mild intellectual disability and developmental delay is observed in
CC some patients. {ECO:0000269|PubMed:28191891}. Note=The disease is
CC caused by variants affecting the gene represented in this entry.
CC -!- MISCELLANEOUS: [Isoform 2]: May be produced at very low levels due to a
CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA
CC decay. {ECO:0000305}.
CC -!- MISCELLANEOUS: [Isoform 3]: May be produced at very low levels due to a
CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA
CC decay. {ECO:0000305}.
CC -!- SIMILARITY: Belongs to the DONSON family. {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AK074964; BAC11320.1; -; mRNA.
DR EMBL; AL157441; CAB75661.1; -; mRNA.
DR EMBL; BC048266; AAH48266.1; -; mRNA.
DR EMBL; AF232673; AAF72947.1; -; mRNA.
DR EMBL; AF232674; AAF72948.1; -; mRNA.
DR EMBL; AF232675; AAF72949.1; -; mRNA.
DR CCDS; CCDS13632.1; -. [Q9NYP3-1]
DR PIR; T46933; T46933.
DR RefSeq; NP_060083.1; NM_017613.3. [Q9NYP3-1]
DR AlphaFoldDB; Q9NYP3; -.
DR BioGRID; 119008; 39.
DR STRING; 9606.ENSP00000307143; -.
DR iPTMnet; Q9NYP3; -.
DR PhosphoSitePlus; Q9NYP3; -.
DR BioMuta; DONSON; -.
DR EPD; Q9NYP3; -.
DR jPOST; Q9NYP3; -.
DR MassIVE; Q9NYP3; -.
DR MaxQB; Q9NYP3; -.
DR PaxDb; Q9NYP3; -.
DR PeptideAtlas; Q9NYP3; -.
DR PRIDE; Q9NYP3; -.
DR ProteomicsDB; 83256; -. [Q9NYP3-1]
DR ProteomicsDB; 83257; -. [Q9NYP3-2]
DR ProteomicsDB; 83258; -. [Q9NYP3-3]
DR Antibodypedia; 35001; 69 antibodies from 15 providers.
DR DNASU; 29980; -.
DR Ensembl; ENST00000303071.10; ENSP00000307143.4; ENSG00000159147.18. [Q9NYP3-1]
DR GeneID; 29980; -.
DR KEGG; hsa:29980; -.
DR MANE-Select; ENST00000303071.10; ENSP00000307143.4; NM_017613.4; NP_060083.1.
DR UCSC; uc002ysk.5; human. [Q9NYP3-1]
DR CTD; 29980; -.
DR DisGeNET; 29980; -.
DR GeneCards; DONSON; -.
DR HGNC; HGNC:2993; DONSON.
DR HPA; ENSG00000159147; Low tissue specificity.
DR MalaCards; DONSON; -.
DR MIM; 251230; phenotype.
DR MIM; 611428; gene.
DR MIM; 617604; phenotype.
DR neXtProt; NX_Q9NYP3; -.
DR OpenTargets; ENSG00000159147; -.
DR Orphanet; 572768; Microcephaly-micromelia syndrome.
DR Orphanet; 572773; Microcephaly-short stature-limb abnormalities syndrome.
DR PharmGKB; PA27459; -.
DR VEuPathDB; HostDB:ENSG00000159147; -.
DR eggNOG; KOG4734; Eukaryota.
DR GeneTree; ENSGT00390000000447; -.
DR InParanoid; Q9NYP3; -.
DR OMA; RCMDPQR; -.
DR OrthoDB; 479613at2759; -.
DR PhylomeDB; Q9NYP3; -.
DR TreeFam; TF318976; -.
DR PathwayCommons; Q9NYP3; -.
DR BioGRID-ORCS; 29980; 741 hits in 1078 CRISPR screens.
DR ChiTaRS; DONSON; human.
DR GenomeRNAi; 29980; -.
DR Pharos; Q9NYP3; Tbio.
DR PRO; PR:Q9NYP3; -.
DR Proteomes; UP000005640; Chromosome 21.
DR RNAct; Q9NYP3; protein.
DR Bgee; ENSG00000159147; Expressed in ventricular zone and 164 other tissues.
DR ExpressionAtlas; Q9NYP3; baseline and differential.
DR Genevisible; Q9NYP3; HS.
DR GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR GO; GO:0005657; C:replication fork; IDA:UniProtKB.
DR GO; GO:0030894; C:replisome; IDA:UniProtKB.
DR GO; GO:0000077; P:DNA damage checkpoint signaling; IMP:UniProtKB.
DR GO; GO:0006260; P:DNA replication; IMP:UniProtKB.
DR GO; GO:0007095; P:mitotic G2 DNA damage checkpoint signaling; IMP:UniProtKB.
DR GO; GO:0033260; P:nuclear DNA replication; IBA:GO_Central.
DR GO; GO:0048478; P:replication fork protection; IMP:UniProtKB.
DR InterPro; IPR024861; Donson.
DR PANTHER; PTHR12972; PTHR12972; 1.
DR PRINTS; PR02064; DONSON.
PE 1: Evidence at protein level;
KW Alternative splicing; Developmental protein; Disease variant; Dwarfism;
KW Nucleus; Phosphoprotein; Reference proteome.
FT CHAIN 1..566
FT /note="Protein downstream neighbor of Son"
FT /id="PRO_0000079979"
FT REGION 1..110
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT MOD_RES 28
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:23186163"
FT MOD_RES 34
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:23186163"
FT VAR_SEQ 263..265
FT /note="SVS -> HGV (in isoform 3)"
FT /evidence="ECO:0000303|PubMed:10773462"
FT /id="VSP_004194"
FT VAR_SEQ 263
FT /note="S -> Y (in isoform 2)"
FT /evidence="ECO:0000303|PubMed:10773462"
FT /id="VSP_004192"
FT VAR_SEQ 264..566
FT /note="Missing (in isoform 2)"
FT /evidence="ECO:0000303|PubMed:10773462"
FT /id="VSP_004193"
FT VAR_SEQ 266..566
FT /note="Missing (in isoform 3)"
FT /evidence="ECO:0000303|PubMed:10773462"
FT /id="VSP_004195"
FT VARIANT 28
FT /note="S -> R (no effect on nuclear localization;
FT complements loss of endogenous DONSON by rescuing the
FT spontaneous fork stalling observed after DONSON depletion;
FT dbSNP:rs768071555)"
FT /evidence="ECO:0000269|PubMed:28191891"
FT /id="VAR_079330"
FT VARIANT 278
FT /note="C -> R (in MISSLA)"
FT /evidence="ECO:0000269|PubMed:28191891"
FT /id="VAR_079331"
FT VARIANT 282
FT /note="Y -> C (in MISSLA; loss of nuclear localization)"
FT /evidence="ECO:0000269|PubMed:28191891"
FT /id="VAR_079332"
FT VARIANT 292
FT /note="F -> L (in MISSLA; loss of nuclear localization;
FT dbSNP:rs779803447)"
FT /evidence="ECO:0000269|PubMed:28191891"
FT /id="VAR_079333"
FT VARIANT 293..566
FT /note="Missing (in MISSLA)"
FT /evidence="ECO:0000269|PubMed:28191891"
FT /id="VAR_079334"
FT VARIANT 417..418
FT /note="Missing (in MISSLA; reduced nuclear localization)"
FT /evidence="ECO:0000269|PubMed:28191891"
FT /id="VAR_079335"
FT VARIANT 419..566
FT /note="Missing (in MISSLA)"
FT /evidence="ECO:0000269|PubMed:28191891"
FT /id="VAR_079336"
FT VARIANT 428..566
FT /note="Missing (in MISSLA)"
FT /evidence="ECO:0000269|PubMed:28191891"
FT /id="VAR_079337"
FT VARIANT 433
FT /note="P -> S (in MISSLA)"
FT /evidence="ECO:0000269|PubMed:28191891"
FT /id="VAR_079338"
FT VARIANT 446
FT /note="M -> T (in MISSLA; reduced protein level; reduced
FT nuclear localization; dbSNP:rs1135401959)"
FT /evidence="ECO:0000269|PubMed:28191891"
FT /id="VAR_079339"
FT VARIANT 489
FT /note="K -> T (in MISSLA; unknown pathological
FT significance; reduced protein level; no effect on nuclear
FT localization; does not complement loss of endogenous DONSON
FT when tested for the rescue of the spontaneous fork stalling
FT observed after DONSON depletion; dbSNP:rs146664036)"
FT /evidence="ECO:0000269|PubMed:28191891"
FT /id="VAR_079340"
FT VARIANT 504
FT /note="E -> K (in MISSLA; dbSNP:rs374688527)"
FT /evidence="ECO:0000269|PubMed:28191891"
FT /id="VAR_079341"
FT VARIANT 543
FT /note="Q -> QK (in MISSLA; reduced nuclear localization)"
FT /evidence="ECO:0000269|PubMed:28191891"
FT /id="VAR_079342"
FT VARIANT 563..566
FT /note="Missing (in MISSLA; unknown pathological
FT significance)"
FT /evidence="ECO:0000269|PubMed:28191891"
FT /id="VAR_079343"
FT CONFLICT 224
FT /note="P -> L (in Ref. 4; AAF72948)"
FT /evidence="ECO:0000305"
FT CONFLICT 437
FT /note="S -> Y (in Ref. 4; AAF72947)"
FT /evidence="ECO:0000305"
FT CONFLICT 557
FT /note="L -> Q (in Ref. 1; BAC11320)"
FT /evidence="ECO:0000305"
SQ SEQUENCE 566 AA; 62747 MW; 5421C43C1E2A03F4 CRC64;
MALSVPGYSP GFRKPPEVVR LRRKRARSRG AAASPPRELT EPAARRAALV AGLPLRPFPA
AGGRGGGSGG GPAAARRNPF ARLDNRPRVA AEPPDGPARE QPEAPVPFLD SNQENDLLWE
EKFPERTTVT ELPQTSHVSF SEPDIPSSKS TELPVDWSIK TRLLFTSSQP FTWADHLKAQ
EEAQGLVQHC RATEVTLPKS IQDPKLSSEL RCTFQQSLIY WLHPALSWLP LFPRIGADRK
MAGKTSPWSN DATLQHVLMS DWSVSFTSLY NLLKTKLCPY FYVCTYQFTV LFRAAGLAGS
DLITALISPT TRGLREAMRN EGIEFSLPLI KESGHKKETA SGTSLGYGEE QAISDEDEEE
SFSWLEEMGV QDKIKKPDIL SIKLRKEKHE VQMDHRPESV VLVKGINTFT LLNFLINSKS
LVATSGPQAG LPPTLLSPVA FRGATMQMLK ARSVNVKTQA LSGYRDQFSL EITGPIMPHS
LHSLTMLLKS SQSGSFSAVL YPHEPTAVFN ICLQMDKVLD MEVVHKELTN CGLHPNTLEQ
LSQIPLLGKS SLRNVVLRDY IYNWRS
